País: Canadá
Língua: inglês
Origem: Health Canada
LETROZOLE
STASON PHARMACEUTICALS INC
L02BG04
LETROZOLE
2.5MG
TABLET
LETROZOLE 2.5MG
ORAL
15/30/100
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0132937001; AHFS:
APPROVED
2012-01-12
_ _ _Zinda-LETROZOLE _ _Page 1 of 64_ PRODUCT MONOGRAPH Pr ZINDA-LETROZOLE Letrozole Tablets USP 2.5 mg Non-steroidal aromatase inhibitor; inhibitor of estrogen biosynthesis; anti-tumour agent Stason Pharmaceuticals, Inc. 11 Morgan Irvine, CA 92618 USA Zinda Pharma Limited 8250 Decarie Suite 110 Montreal, QC H4P 2P5 Date of Revision: September 3, 2014 Submission Control No: 171882 _ _ _Zinda-LETROZOLE _ _Page 2 of 64_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...................................................... ..3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 24 DOSAGE AND ADMINISTRATION ............................................................................. 27 OVERDOSAGE ............................................................................................................... 28 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 28 STORAGE AND STABILITY ......................................................................................... 31 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 31 PART II: SCIENTIFIC INFORMATION .............................................................................. 32 PHARMACEUTICAL INFORMATION ......................................................................... 32 CLINICAL TRIALS .................................................................. Leia o documento completo